220 related articles for article (PubMed ID: 34586888)
1. Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in Apc
Yang K; Zhu J; Luo HH; Yu SW; Wang L
Int J Immunopathol Pharmacol; 2021; 35():20587384211038345. PubMed ID: 34586888
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.
Liu LS; Bai XQ; Gao Y; Wu Q; Ren Z; Li Q; Pan LH; He NY; Peng J; Tang ZH
J Alzheimers Dis; 2017; 57(3):723-734. PubMed ID: 28304296
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
Qi Z; Hu L; Zhang J; Yang W; Liu X; Jia D; Yao Z; Chang L; Pan G; Zhong H; Luo X; Yao K; Sun A; Qian J; Ding Z; Ge J
Circulation; 2021 Jan; 143(1):45-61. PubMed ID: 32988222
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
6. Effect of SOCS3 on lung injury in rats with severe acute pancreatitis through regulating JAK2/STAT3 signaling pathway.
Qin MZ; Qin MB; Liang ZH; Tang GD
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10123-10131. PubMed ID: 31799684
[TBL] [Abstract][Full Text] [Related]
7. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
9. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of resveratrol on obesity-related osteoarthritis via alleviating JAK2/STAT3 signaling pathway is independent of SOCS3.
Jiang M; He J; Gu H; Yang Y; Huang Y; Xu X; Liu L
Toxicol Appl Pharmacol; 2020 Feb; 388():114871. PubMed ID: 31881177
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit.
Yang X; Jia J; Yu Z; Duanmu Z; He H; Chen S; Qu C
BMC Cardiovasc Disord; 2020 Mar; 20(1):133. PubMed ID: 32169038
[TBL] [Abstract][Full Text] [Related]
12. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes.
Choe JY; Park KY; Park SH; Lee SI; Kim SK
Arthritis Res Ther; 2013 Feb; 15(1):R26. PubMed ID: 23406906
[TBL] [Abstract][Full Text] [Related]
13. A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice.
Essalmani R; Weider E; Marcinkiewicz J; Chamberland A; Susan-Resiga D; Roubtsova A; Seidah NG; Prat A
Biol Chem; 2018 Nov; 399(12):1363-1374. PubMed ID: 30044755
[TBL] [Abstract][Full Text] [Related]
14. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.
Li XD; Li XM; Gu JW; Sun XC
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5153-5159. PubMed ID: 29228427
[TBL] [Abstract][Full Text] [Related]
15. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lncRNA DILC attenuates neuropathic pain via the SOCS3/JAK2/STAT3 pathway.
Liu Y; Feng L; Ren S; Zhang Y; Xue J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510145
[TBL] [Abstract][Full Text] [Related]
17. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
18. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
19. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma.
Peng HY; Cheng YC; Hsu YM; Wu GH; Kuo CC; Liou JP; Chang JY; Jin SL; Shiah SG
PLoS One; 2016; 11(7):e0158440. PubMed ID: 27367272
[TBL] [Abstract][Full Text] [Related]
20. SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells.
Li MZ; Lai DH; Zhao HB; Chen Z; Huang QX; Situ J
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3005-3011. PubMed ID: 28742207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
